Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Heart failure
- Focus Therapeutic Use
- Acronyms PRIME
- 11 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 Jan 2018.
- 11 Jan 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
- 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.